Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions

Priya Jayachandran(Los Angeles Medical Center), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center)

Oncogene

January 18, 2023

10.1038/s41388-022-02584-4

Cited by 52

Related Papers

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

|The Lancet Oncology|2017|2.8k

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

|Journal of Clinical Oncology|2018|2.1k

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

|JAMA|2017|891

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer

|JAMA Oncology|2016|722

Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

|The Oncologist|2007|418